Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...
Biogen (BIIB) just cleared two important milestones, with FDA approval of a new High Dose Regimen for SPINRAZA in spinal muscular atrophy and positive Phase 2 data for litifilimab in cutaneous lupus ...
Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.
Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.
Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving ...
Using a registry of real-world patients with lupus nephritis, investigators studied trajectories of kidney function decline over a decade.
Curtis’s connection to lupus is deeply personal—rooted in a commitment to honoring his late daughter, Rashara. After her ...
The walk will take place Saturday, March 21 at Tyrrell Park, bringing together survivors, families and supporters to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results